搜尋
Lipocine Inc
LPCN添加自選
2.120USD
+0.010+0.47%
收盤 07-31 16:00（美東）報價延遲15分鐘
15.85M總市值
虧損本益比TTM
關於 Lipocine Inc 公司
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Lipocine Inc簡介
公司代碼LPCN
公司名稱Lipocine Inc
上市日期Mar 21, 2014
CEOPatel (Mahesh V)
員工數量16
證券類型Ordinary Share
年結日Mar 21
公司地址675 S Arapeen Dr Ste 202
城市SALT LAKE CITY
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編84108-1295
電話18019947383
網址https://www.lipocine.com/
公司代碼LPCN
上市日期Mar 21, 2014
CEOPatel (Mahesh V)
Lipocine Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
203.80K
+79.98%
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
160.68K
+31.12%
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.86K
+9.40%
Ms. Krista Fogarty
Ms. Krista Fogarty
Principal Accounting Officer, Corporate Controller
Principal Accounting Officer, Corporate Controller
1.40K
+23.64%
Dr. Richard Dana Ono, Ph.D.
Dr. Richard Dana Ono, Ph.D.
Independent Director
Independent Director
831.00
--
Mr. Jeffrey A. (Jeff) Fink
Mr. Jeffrey A. (Jeff) Fink
Independent Director
Independent Director
386.00
--
Dr. Jill M. Jene, Ph.D.
Dr. Jill M. Jene, Ph.D.
Independent Director
Independent Director
--
--
Mr. Spyros Papapetropoulos, M.D., Ph.D.
Mr. Spyros Papapetropoulos, M.D., Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
203.80K
+79.98%
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
160.68K
+31.12%
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.86K
+9.40%
Ms. Krista Fogarty
Ms. Krista Fogarty
Principal Accounting Officer, Corporate Controller
Principal Accounting Officer, Corporate Controller
1.40K
+23.64%
Dr. Richard Dana Ono, Ph.D.
Dr. Richard Dana Ono, Ph.D.
Independent Director
Independent Director
831.00
--
Mr. Jeffrey A. (Jeff) Fink
Mr. Jeffrey A. (Jeff) Fink
Independent Director
Independent Director
386.00
--
常見問題
Lipocine Inc的前五大股東是誰？
Lipocine Inc的前五大股東如下：Mr. John W. Higuchi
有多少機構持有Lipocine Inc(LPCN)的股份？
截至2026Q1，共有45家機構持有Lipocine Inc的股份，合計持有的股份價值約為2.08M，占公司總股份的25.27% 。與2025Q4相比，機構持股有所增加，增幅為1533872.00。